Pharmacophore-Based Virtual Screening for Identification of Adenosine Deaminase Inhibitors
Iranian Journal of Pharmaceutical Research · 20.07.2026 · 25 (1)
DOI: 10.5812/ijpr-170515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 20.07.2026. Verfasst von Saba Ahmadi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adenosine deaminase (ADA) is a key enzyme in purine metabolism, and abnormal ADA activity has been associated with various diseases, including severe combined immunodeficiency, cancer, neurodegenerative disorders, and liver diseases.
Objectives
This study employed a pharmacophore-based virtual screening strategy to identify novel ADA inhibitors from an in-house library.
Methods
Two crystal structures of ADA co-crystallized with erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and pentostatin were used to develop a pharmacophore model. The validated model was used to screen an in-house library. The resulting hits were further evaluated using molecular docking with AutoDock Vina. The compound with the highest binding affinity in the docking study was subsequently assessed by molecular dynamics (MD) simulation and in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis.
Results
The validated pharmacophore model comprised one hydrogen bond donor, one hydrogen bond acceptor, and one aromatic ring. When evaluated against the DUDE-Z database set, the model demonstrated acceptable sensitivity and specificity, with an enrichment factor of 23. Screening of the in-house library identified four promising hits. Compound 154 was the most notable hit because of its potent binding affinity and favorable interactions with key amino acids in the ADA active site. MD simulations showed that the ADA–compound 154 complex remained stable throughout the 150 ns simulation. MM-GBSA energy analysis indicated favorable binding driven by van der Waals and electrostatic interactions. Per-residue decomposition analysis identified critical residues contributing to complex stabilization. Compared with reference ADA inhibitors, compound 154 exhibited similar drug-likeness and pharmacokinetic properties, although further toxicity optimization may be required.
Conclusions
These results suggest that compound 154 is a promising lead for developing new ADA inhibitors and underscore the effectiveness of computational methods in drug discovery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Research Center for War-Affected People, Tehran University of Medical Sciences, Tehran, Iran.
- Central Research Laboratories, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Saba Ahmadi, Mona Khoramjouy, Salimeh Amidi, Farzad Kobarfard
Zitieren
APA
Ahmadi, S., Khoramjouy, M., Jafarian, A., Shahhosseini, S., Amidi, S., & Kobarfard, F. (2026). Pharmacophore-Based Virtual Screening for Identification of Adenosine Deaminase Inhibitors. Iranian Journal of Pharmaceutical Research, 25(1). https://doi.org/10.5812/ijpr-170515
Vancouver
Ahmadi S, Khoramjouy M, Jafarian A, Shahhosseini S, Amidi S, Kobarfard F. Pharmacophore-Based Virtual Screening for Identification of Adenosine Deaminase Inhibitors. Iranian Journal of Pharmaceutical Research. 2026;25(1). doi:10.5812/ijpr-170515
BibTeX
@article{Ahmadi2026,
author = {Ahmadi, Saba and Khoramjouy, Mona and Jafarian, Arefeh and Shahhosseini, Soraya and Amidi, Salimeh and Kobarfard, Farzad},
title = {Pharmacophore-Based Virtual Screening for Identification of Adenosine Deaminase Inhibitors},
journal = {Iranian Journal of Pharmaceutical Research},
year = {2026},
volume = {25},
number = {1},
doi = {10.5812/ijpr-170515}
}
EUVIMED